Abstract： Objective: To investigate the effect of different concentrations of mouse nerve growth factor (mNGF) in eye drops on rabbits' central corneal nerve regeneration after laser in situ keratomileusis. Methods: In this experimental study, 39 New Zealand white rabbits were included and randomly assigned to 5 groups: normal saline group (normal saline, 7 rabbits, 14 eyes), hycosan group (0.1% hycosan, 8 rabbits, 16 eyes), NGF50 group (50 µg/mL, 8 rabbits, 16 eyes), NGF100 group (100 µg/mL, 8 rabbits, 16 eyes) and NGF200 group (200 µg/mL, 8 rabbits, 16 eyes). Central corneal subbasal nerve densities (SNDs) and superficial stroma nerve densities (SSNDs) were measured by confocal microscopy Ⅲ and were compared before surgery, 1 week, 1 month, 2 months and 3 months after surgery. Repeated measures and one-way analysis of variance were used for comparing the differences between different time points for these groups. Results: The differences in preoperative SNDs and SSNDs in the normal saline group, hycosan group, NGF50 group, NGF100 group and NGF200 group were not statistically significant (F=1.371, P=0.252; F=0.372, P=0.828). Compared with preoperative values, all nerve parameters of the 5 groups decreased at 1 week (all P<0.05) postoperatively, but the differences among the 5 groups were not statistically significant (F=1.905, P=0.119; F=0.923, P=0.455). SNDs in the NGF100 group and NGF200 group were significantly higher than in the other 3 groups at 1 month after surgery (all P<0.05); SNDs in the NGF200 group were significantly higher than in the other groups at 2 months and 3 months postoperatively (all P<0.05). SSNDs in the NGF200 group were significantly higher than in the other groups at 1 and 2 months after surgery (all P<0.05). At 3 months after surgery, SSNDs in the NGF200 group were significantly higher than those in the NGF50 group and the 2 nonNGF groups (all P<0.05). The NGF50 group and NGF100 group had higher densities than the 2 non-NGF groups (all P<0.05). Conclusions: mNGF eye drops have a significant effect on promoting corneal nerve repair in different periods following LASIK, and the effect is highest in the NGF200 group.
Liu M, Chen Y, Wang D, et al. Clinical outcomes after smile and femtosecond laser-assisted lasik for myopia and myopic astigmatism: A prospective randomized comparative study. Cornea, 2016, 35(2): 210-216. DOI: 10.1097/ ICO.0000000000000707.
[2]
Moshirfar M, Jehangir N, Fenzl CR, et al. LASIK enhancement: Clinical and surgical management. J Refract Surg, 2017, 33(2): 116-127. DOI: 10.3928/1081597X-20161202-01.
[3]
Shen Z, Zhu Y, Song X, et al. Dry eye after small incision lenticule extraction (SMILE) versus femtosecond laser-assisted in situ keratomileusis (FS-LASIK) for myopia: A meta-analysis. PLoS One, 2016, 11(12): e0168081. DOI: 10.1371/journal. pone.0168081.
Mai EL, Lian IB, Chang DC. Assessment of contrast sensitivity loss after intrastromal femtosecond laser and LASIK procedure. Int J Ophthalmol 2016, 9(12): 1798-1801. DOI: 10.18240/ ijo.2016.12.16.
Wang B, Naidu RK, Chu R, et al. Dry eye disease following refractive surgery: a 12-month follow-up of SMILE versus FSLASIK in high myopia. J Ophthalmol, 2015, 2015: 132417. DOI: 10.1155/2015/132417.
Benson N, Matsuura T, Smirnov S, et al. Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology. Interface Focus, 2013, 3(2): 20120071. DOI: 10.1098/ rsfs.2012.0071.
[10]
Sone Y, Takatori S, Ochi E, et al. Nerve growth factor facilitates the innervation of perivascular nerves in tumor-derived neovasculature in the mouse cornea. Pharmacology, 2017, 99(1- 2): 57-66. DOI: 10.1159/000450582.
[11]
Park JH, Kang SS, Kim JY, et al. Nerve growth factor attenuates apoptosis and inflammation in the diabetic cornea. Invest Ophthalmol Vis Sci, 2016, 57(15): 6767-6775. DOI: 10.1167/ iovs.16-19747.
[12]
Wu Y, Chu R, Zhou X, et al. Determination of the nerve growth factor level in the central cornea after LASIK and Epi-LASIK treatment in a rabbit model system. Cornea, 2009, 28(10): 1144- 1148. DOI: 10.1097/ICO.0b013e3181a2a7e3.
[13]
Lambiase A, Coassin M, Sposato V, et al. NGF topical application in patients with corneal ulcer does not generate circulating NGF antibodies. Pharmacol Res, 2007, 56(1): 65-69. DOI: 10.1016/j.phrs.2007.03.007.
[14]
Coassin M, Lambiase A, Costa N, et al. Efficacy of topical nerve growth factor treatment in dogs affected by dry eye. Graefes Arch Clin Exp Ophthalmol, 2005, 243(2): 151-155. DOI: 10.1007/s00417-004-0955-2.
[15]
Cellini M, Bendo E, Bravetti GO, et al. The use of nerve growth factor in surgical wound healing of the cornea. Ophthalmic Res, 2006, 38(4): 177-181. DOI: 10.1159/000092626.
[16]
Patel DV, McGhee CN. In vivo confocal microscopy of human corneal nerves in health, in ocular and systemic disease, and following corneal surgery: A review. Br J Ophthalmol, 2009, 93(7): 853-860. DOI: 10.1136/bjo.2008.150615.
Ma K, Yan N, Huang Y, et al. Effects of nerve growth factor on nerve regeneration after corneal nerve damage. Int J Clin Exp Med, 2014, 7(11): 4584-4589.
[19]
Joo MJ, Yuhan KR, Hyon JY, et al. The effect of nerve growthfactor on corneal sensitivity after laser in situ keratomileusis. Arch Ophthalmol, 2004, 122(9): 1338-1341. DOI: 10.1001/ archopht.122.9.1338.
[20]
Ferrari MP, Mantelli F, Sacchetti M, et al. Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial. BioDrugs, 2014, 28(3): 275-283. DOI: 10.1007/ s40259-013-0079-5.
[21]
Cruzat A, Qazi Y, Hamrah P. In vivo confocal microscopy of corneal nerves in health and disease. Ocul Surf, 2017, 15(1): 15- 47. DOI: 10.1016/j.jtos.2016.09.004.
Li B, Sheng X, Bao L, et al. Seasonal changes in expression of nerve growth factor and its receptors TrkA and p75 in the ovary of wild ground squirrel (Citellus dauricus Brandt). J Ovarian Res, 2014, 7: 3. DOI: 10.1186/1757-2215-7-3.
[24]
Blanco-Mezquita T, Martinez-Garcia C, Proença R, et al. Nerve growth factor promotes corneal epithelial migration by enhancing expression of matrix metalloprotease-9. Invest Ophthalmol Vis Sci, 2013, 54(6): 3880-3890. DOI: 10.1167/ iovs.12-10816.
[25]
Manni L, Rocco ML, Bianchi P, et al. Nerve growth factor: basic studies and possible therapeutic applications. Growth Factors, 2013, 31(4): 115-122. DOI: 10.3109/08977194.2013.804073.
[26]
Nucci C, Strouthidis NG, Khaw PT. Neuroprotection and other novel therapies for glaucoma. Curr Opin Pharmacol, 2013, 13(1): 1-4. DOI: 10.1016/j.coph.2012.10.009.
[27]
Shaheen BS, Bakir M, Jain S. Corneal nerves in health and disease. Surv Ophthalmol, 2014, 59(3): 263-285. DOI: 10.1016/ j.survophthal.2013.09.002.
[28]
Chao C, Golebiowski B, Zhao X, et al. Long-term effects of LASIK on corneal innervation and tear neuropeptides and the associations with dry eye. J Refract Surg, 2016, 32(8): 518-524. DOI: 10.3928/1081597X-20160603-01.
[29]
Levitt AE, Galor A, Weiss JS, et al. Chronic dry eye symptoms after LASIK: parallels and lessons to be learned from other persistent post-operative pain disorders. Mol Pain, 2015, 11: 21. DOI: 10.1186/s12990-015-0020-7.
[30]
Rosenfeld SI. Evaluation and management of post-LASIK dry eye syndrome. Int Ophthalmol Clin, 2010, 50(3): 191-199. DOI: 10.1097/IIO.0b013e3181e2469b.
[31]
Kobashi H, Kamiya K, Shimizu K. Dry eye after small incision lenticule extraction and femtosecond laser-assisted LASIK: Meta-analysis. Cornea, 2017, 36(1): 85-91. DOI: 10.1097/ ICO.0000000000000999.
[32]
Lee HK, Lee KS, Kim HC, et al. Nerve growth factor concentration and implications in photorefractive keratectomy vs laser in situ keratomileusis. Am J Ophthalmol, 2005, 139(6): 965-971. DOI: 10.1016/j.ajo.2004.12.051.
[33]
Klenkler B, Sheardown H, Jones L. Growth factors in the tear film: role in tissue maintenance, wound healing, and ocular pathology. Ocul Surf, 2007, 5(3): 228-239. DOI: 10.1016/s1542- 0124(12)70613-4.
[34]
Lisi S, Sisto M, Ribatti D, et al. Chronic inflammation enhances NGF-β/TrkA system expression via EGFR/MEK/ERK pathway activation in Sjögren's syndrome. J Mol Med (Berl), 2014, 92(5): 523-537. DOI: 10.1007/s00109-014-1130-9.
浙公网安备 33030202001892号